As the year comes to a close, a new chapter in the ongoing battle against COVID-19 unfolds with the emergence of the JN.1 variant. Former AIIMS director and senior pulmonologist Dr. Randeep Guleria sheds light on the situation, providing insights into the characteristics and impact of this evolving sub-variant.
This should be India’s JN. 1 protocol. This is how science is presented. Clear,concise,confident and correct! pic.twitter.com/UL8VfUoCXO
— DrRavi (@DrGodseRavi1) December 25, 2023
The Rise of JN.1 in India
India, grappling with the persistent challenges posed by the pandemic, now faces the emergence of the JN.1 variant. With 22+ reported cases across the country, concerns about its transmissibility and potential implications have come to the forefront.
Dr. Guleria (Former AIIMS director and senior pulmonologis)t, a respected voice in the medical community, acknowledges that the JN.1 variant is more transmissible, indicating a gradual dominance. However, amidst the heightened concerns, he offers a reassuring note – the variant is not causing severe infections or hospitalizations. The symptoms primarily manifest in the upper airways, encompassing fever, cough, cold, sore throat, running nose, and body aches.
Senior Pulmonologist Dr Randeep Guleria on covid 19 new variant jn.1#MedTwitter #MedEd #MedX pic.twitter.com/Aie0DTu0I1
— Dr Aisha Sharma (@mishalmedico) December 25, 2023
WHO’s Classification and Global Perspective
The World Health Organisation (WHO) has classified the JN.1 variant as a ‘variant of interest.’ Despite its increased prevalence, the global health body emphasizes that the overall risk remains low based on current evidence. This nuanced classification seeks to balance vigilance with a measured response.
WHO classifies COVID variant JN.1 as a Variant of Interest due to "rapidly increasing spread" pic.twitter.com/jPNWvcTjCf
— BNO News (@BNOFeed) December 19, 2023
Vaccination and INSACOG’s Guidance
India SARS-CoV-2 Genomics Consortium (INSACOG) chief Dr. N.K. Arora weighs in on the vaccination strategy, stating that there is currently no need for an additional fourth booster dose specifically targeting JN.1. He emphasizes that individuals over 60 with comorbidities and high-risk patients in this age group may consider a precautionary third dose if not administered already. Dr. Arora advocates for precaution rather than panic.
Serum Institute of India’s Plans
As India grapples with a surge in COVID-19 cases, attributed in part to the JN.1 variant, the Union Health Ministry directs states to be alert and prepared. However, in contrast to potential expectations, there is no recommendation for an additional booster dose at this time.
The Serum Institute of India (SII) addresses the evolving situation, stating its intention to obtain licensure for the XBB1 COVID variant vaccine, closely aligned with the JN.1 variant.
The spike in COVID-19 cases came amid a rise in sub-variant JN.1 cases across the country. pic.twitter.com/P7jz8XFzWV
— ET NOW (@ETNOWlive) December 25, 2023
Also Read: Noble Prize in Medicine 2023: How Katalin and Weissman Developed Covid Vaccines
Global Context and WHO’s Epidemiological Update
The World Health Organisation’s recent epidemiological update highlights a 52% increase in new cases globally during a 28-day period. While the number of new deaths decreased by 8%, the emergence of new variants, including JN.1, remains a significant concern.
The JN.1 variant makes its presence felt in India and globally, the situation shal require a vigilant yet measured response. The collaborative efforts of health authorities, vaccination strategies, and public awareness play crucial roles in navigating the challenges posed by this evolving chapter in the fight against COVID-19 and it’s variants.
[…] Also Read: COVID 19 Returns: All you need to know about the JN.1 Variant […]